Abstract 564P
Background
The current National Comprehensive Cancer Network guideline recommends Afatinib and/or Osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC carrying EGFR p.G719X mutation. In the absence of head-to-head trials comparing Afatinib with Osimertinib in EGFR p.G719X mutant patients, it is unclear which regimen is the preferred treatment option.
Methods
A large cohort of 4228 treatment-naïve patients with lung cancer who underwent targeted next-generation sequencing (NGS) testing was screened in terms of the EGFR p.G719X mutation. Ba/F3 cells stably expressing the EGFR p.G719A mutation with either the p.E709K mutation or not were created to investigate the response to EGFR-TKIs. The patient-derived lung cancer organoid (LCO) cultures were created, and the corresponding drug treatments and sensitivity (DTS) test was performed.
Results
EGFR p.G719X mutation occurs with a prevalence of 2.56%. EGFR p.E709X(30.4%) composed the most frequent co-occurring EGFR mutation. Co-occurring EGFR p.E709X mutations exerted a detrimental effect on outcomes in Osimertinib-treated patients (G719X/E709X VS. G719X; ORR: 0.00% VS. 47.62%, P<0.001; mPFS:7.18 VS. 14.2 months, P=0.042; respectively). In contrast, no significant difference was found in the treatment efficacy between EGFR p.G719X/E709X and EGFR p.G719X patients upon Afatinib treatment (G719X/E709X VS. G719X; ORR: 71.43% VS. 56.67%, P=0.99; mPFS:14.7 VS. 15.8 months, P=0.69; respectively). In vitro experiments elucidated a resistant drug sensitivity and poor inhibition of EGFR phosphorylation in Ba/F3 cells expressing EGFR p.G719A/E709K mutation treated with the third-generation EGFR-TKIs. The DTS result of LCO revealed that the second-generation EGFR-TKIs may be superior to first or third-generation EGFR-TKIs for patients with EGFR p.G719X/E709X mutation.
Conclusions
We enrolled the largest available dataset of EGFR p.G719X-mutant patients with NSCLC. The variable sensitivity of EGFR p.G719X mutation to different EGFR TKIs indicates that a personalized treatment strategy should be undertaken in patients depending on the status of underlying co-existing EGFR p.E709X mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract